JNJ Chart

1 Month

	Date	Diff	Articles
	2025-04-04	-4.12 %	Johnson & Johnson (JNJ) stock fell by 4.12% last night, attributed to lower trading volumes and possible investor concerns about the company’s recent performance despite its healthy market position and product offerings in the healthcare sector.
Johnson & Johnson (JNJ) stock fell by 4.12% last night, attributed to lower trading volumes and possible investor concerns about the company’s recent performance despite its healthy market position and product offerings in the healthcare sector. The article discusses how Johnson & Johnson's stock, along with other Swedish companies, has dropped by 4.12% due to the impact of President Donald Trump's tariffs on imports, which has raised concerns about potential economic slowdown and retaliatory measures. The decline in JNJ's stock is primarily attributed to the broad market reaction to the tariffs and fears of a global recession. Johnson & Johnson's stock (JNJ) declined by 4.12% likely due to downgrades in price targets by several analysts, with Morgan Stanley lowering theirs significantly, which may have influenced investor sentiment negatively. Johnson & Johnson's stock (JNJ) fell by 4.12% following a series of mixed ratings and price target adjustments from various analysts, despite reporting earnings that beat consensus estimates.
	2025-04-03	+2.87 %	The article discusses a bullish outlook on Flex Ltd. (FLEX), highlighting its strong cash flow, efficient operations, and market positioning despite recent stock declines, which may suggest underlying potential value despite a decline in revenues. Regarding Johnson & Johnson (JNJ), the article does not explicitly explain why its stock increased by 2.87%; however, stock prices generally rise due to positive market sentiment, strong earnings reports, favorable news, or investor confidence in the company's stability and growth prospects.
The article discusses a bullish outlook on Flex Ltd. (FLEX), highlighting its strong cash flow, efficient operations, and market positioning despite recent stock declines, which may suggest underlying potential value despite a decline in revenues. Regarding Johnson & Johnson (JNJ), the article does not explicitly explain why its stock increased by 2.87%; however, stock prices generally rise due to positive market sentiment, strong earnings reports, favorable news, or investor confidence in the company's stability and growth prospects.
	2025-04-02	+1.38 %	Johnson & Johnson's stock rose 1.38% after previously experiencing a decline due to unsuccessful settlement efforts regarding liability cases related to its baby powder and talc products, indicating potential recovery or investor optimism despite recent legal challenges.
Johnson & Johnson's stock rose 1.38% after previously experiencing a decline due to unsuccessful settlement efforts regarding liability cases related to its baby powder and talc products, indicating potential recovery or investor optimism despite recent legal challenges. Johnson & Johnson (JNJ) stock rose 1.38% despite a broader market decline driven by uncertainty over potential tariffs, likely due to investor optimism following previous volatility and recent overall market fluctuations. The rise in JNJ's stock could be attributed to investors seeking potential opportunities as market reactions to economic news have created buying pressure amid the uncertainty, contrasting with the negative sentiment affecting other sectors. Johnson & Johnson (JNJ) stock rose 1.38% despite a previous 7% drop following a legal setback, as analysts see the stock as an attractive buying opportunity at its current price of approximately $155 due to its strong operating performance, moderate valuation, and resilience compared to the broader market. The increase in JNJ stock may be attributed to positive investor sentiment regarding its favorable valuation and performance metrics despite ongoing litigation risks.
	2025-04-01	-7.59 %	Johnson & Johnson's (JNJ) stock fell by -7.59% due to concerns over the potential impact of new tariffs proposed by the Trump administration on the pharmaceutical sector, which could lead to significant commercial challenges for companies operating in Ireland and affect their investment decisions in the long term.
Johnson & Johnson's (JNJ) stock fell by -7.59% due to concerns over the potential impact of new tariffs proposed by the Trump administration on the pharmaceutical sector, which could lead to significant commercial challenges for companies operating in Ireland and affect their investment decisions in the long term. Johnson & Johnson (JNJ) stock fell by 7.59% following a U.S. bankruptcy judge's rejection of the company's $10 billion proposal to resolve numerous lawsuits claiming that its talc products, including baby powder, caused ovarian cancer. Johnson & Johnson (JNJ) stock dropped 7.59% after a judge rejected the company's proposed bankruptcy plan aimed at settling thousands of claims linked to its talc products allegedly causing ovarian cancer. Johnson & Johnson's stock fell by 7.59% after a judge rejected the company's $10 billion proposal to settle numerous lawsuits related to talc products. Johnson & Johnson's stock fell nearly 5% due to a federal judge denying its settlement plan related to baby powder containing talc.
	2025-03-28	+0.36 %	Johnson & Johnson's (JNJ) stock rose by 0.36% possibly due to positive developments in their partnered clinical trials, particularly the collaboration with LAVA Therapeutics on innovative cancer treatments that may enhance shareholder value in the biopharmaceutical sector.
Johnson & Johnson's (JNJ) stock rose by 0.36% possibly due to positive developments in their partnered clinical trials, particularly the collaboration with LAVA Therapeutics on innovative cancer treatments that may enhance shareholder value in the biopharmaceutical sector. Johnson & Johnson (JNJ) stock increased by 0.36% amidst a projected growth in the global antiseptic products market, which is driven by heightened hygiene awareness post-pandemic, the rising prevalence of chronic diseases, and expanding applications in healthcare and consumer use.
	2025-03-27	+0.87 %	Johnson & Johnson (JNJ) stock rose by 0.87% likely due to positive market sentiments surrounding the pharmaceutical sector, amidst strong trading volumes and continued interest in healthcare innovations and developments.
Johnson & Johnson (JNJ) stock rose by 0.87% likely due to positive market sentiments surrounding the pharmaceutical sector, amidst strong trading volumes and continued interest in healthcare innovations and developments.
	2025-03-26	+0.43 %	Johnson & Johnson (JNJ) stock rose by 0.43% largely due to positive financial results and growth milestones announced by Alvotech, a biotech company specializing in biosimilars, indicating strong performance and future potential in the biotechnology sector that JNJ is associated with.
Johnson & Johnson (JNJ) stock rose by 0.43% largely due to positive financial results and growth milestones announced by Alvotech, a biotech company specializing in biosimilars, indicating strong performance and future potential in the biotechnology sector that JNJ is associated with. Johnson & Johnson's (JNJ) stock rose by 0.43% due to positive financial results and significant developments in Alvotech, a biotechnology company that reported record product sales and milestones, indicating strong growth potential in the biosimilar market, which could have positive implications for JNJ's affiliates or competitors in that space. Johnson & Johnson's stock (JNJ) rose by 0.43% following the announcement of Band-Aid's new collection featuring iconic artworks, which indicates a strategic shift towards targeting adult consumers and transforming bandages into fashion accessories. The stock likely went up due to positive market reception of this innovative consumer product strategy, reflecting the company's ability to adapt and attract a broader customer base.
	2025-03-25	-1.39 %	Johnson & Johnson (JNJ) stock fell by 1.39% partly due to investor concerns over increasing government regulation in the healthcare sector, as discussions around controlling drug prices and limiting pharmaceutical companies' profits could negatively impact their future earnings.
Johnson & Johnson (JNJ) stock fell by 1.39% partly due to investor concerns over increasing government regulation in the healthcare sector, as discussions around controlling drug prices and limiting pharmaceutical companies' profits could negatively impact their future earnings.
	2025-03-24	-0.21 %	Johnson & Johnson (JNJ) stock was down by 0.21% last night, but the article does not specify the exact reasons for this decline. Potential factors could include market trends, investor sentiment, or company-specific news, but these details are not provided in the summary.
Johnson & Johnson (JNJ) stock was down by 0.21% last night, but the article does not specify the exact reasons for this decline. Potential factors could include market trends, investor sentiment, or company-specific news, but these details are not provided in the summary. Johnson & Johnson (JNJ) stock declined by 0.21% due to investor concerns regarding ongoing developments in its subsidiary partnerships and the merger activities of Salarius Pharmaceuticals with Decoy Therapeutics, which may influence the market's perception of JNJ's future prospects in the biopharmaceutical sector. Johnson & Johnson (JNJ) stock was down by -0.21%, likely due to market reactions that may encompass broader factors affecting the healthcare sector, regulatory uncertainties, or potential impacts from developments in related companies like OncoCyte Corporation, which recently made advancements in their transplant rejection diagnostics that could shift competitive dynamics in the industry. Johnson & Johnson (JNJ) stock was down 0.21% due to fluctuations in market performance among healthcare stocks and broader industry trends affecting investor sentiment.
	2025-03-21	+0.37 %	Johnson & Johnson (JNJ) stock increased by 0.37% following recent announcements of significant U.S. investments, including the groundbreaking of a high-tech facility in North Carolina, which promise to create jobs and bolster manufacturing in the U.S. economy.
Johnson & Johnson (JNJ) stock increased by 0.37% following recent announcements of significant U.S. investments, including the groundbreaking of a high-tech facility in North Carolina, which promise to create jobs and bolster manufacturing in the U.S. economy.